Business Context and Reporting Period
Company: EXICURE, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: March 3, 2021
Reporting Period: Single event date (March 3, 2021)
Business Context: The filing discloses a regulatory milestone regarding the company's drug development pipeline. Exicure is an emerging growth company listed on the Nasdaq Stock Market under the symbol XCUR.
Key Financial Metrics
This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is a regulatory approval rather than a financial variance:
- Regulatory Milestone: On March 3, 2021, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Exicure's candidate drug, Cavrotolimod (AST-008).
- Indication: The designation is for the treatment of patients with Merkel cell carcinoma.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) announcing the FDA designation but does not include forward-looking guidance, financial outlook, or specific risk factors within the body of this 8-K text.
Legal Disclaimer: The information in Item 7.01 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on the Orphan Drug Designation benefits and next steps for Cavrotolimod.
- Review the company's most recent 10-K or 10-Q filings for current financial health, cash runway, and debt levels, as this 8-K contains no financial data.
- Confirm the status of the clinical trials for Cavrotolimod (AST-008) in relation to the new FDA designation.
- Check for any subsequent filings regarding the impact of this designation on the company's valuation or partnership opportunities.